RESNA Welcomes Three Members to Board of Directors The Rehabilitation Engineering and Assistive Technology Society of North America (RESNA) has announced that three newly elected board members will begin their terms on Aug. 1. In a July 12 social media post, RESNA welcomed Ana Allegretti, Ph.D., OTR, ATP; Julienne Brown, PT, DPT, NCS, ATP/SMS; and…
Briefly: RESNA Elects Board Members; FDA Asks Sarepta Therapeutics to Stop Shipments of Duchenne MD Drug
FDA Approves Treatment for SOD1 ALS
The new treatment is for people whose ALS is caused by a known genetic mutation.
The U.S. Food & Drug Administration (FDA) has approved a treatment for people with amyotrophic lateral sclerosis (ALS) caused by a mutation in the superoxide dismutase 1 (SOD1) gene. The FDA described Qalsody (also known as tofersen) as “an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein.” Qalsody is administered…